Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Vorinostat - Merck & Co

Drug Profile

Vorinostat - Merck & Co

Alternative Names: L-001079038; MK 0683; SAHA; Suberanilohydroxamic acid; Suberoylanilide hydroxamic acid; Zolinza

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Columbia University; Memorial Sloan-Kettering Cancer Center
  • Developer Banyu; Bayer; Columbia University; Dana-Farber Cancer Institute; Fred Hutchinson Cancer Research Center; Groupe Francophone des Myelodysplasies; H. Lee Moffitt Cancer Center and Research Institute; Indiana University; Massachusetts General Hospital; Memorial Sloan-Kettering Cancer Center; Merck & Co; National Center for Tumor Diseases; Roswell Park Cancer Institute; Stanford University; Takeda; University Hospital Heidelberg; University of North Carolina at Chapel Hill; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Hydroxamic acids; Small molecules
  • Mechanism of Action Histone deacetylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cutaneous T-cell lymphoma; Multiple myeloma; Malignant-mesothelioma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Cutaneous T-cell lymphoma
  • Phase II Acute myeloid leukaemia; B-cell lymphoma; Breast cancer; Glioma; HIV-1 infections; Multiple myeloma; Myelodysplastic syndromes; Non-Hodgkin's lymphoma
  • Phase I/II Leukaemia; Lymphoma; Solid tumours
  • No development reported Brain metastases; Colorectal cancer; Glioblastoma; Gliosarcoma; Hodgkin's disease
  • Discontinued Gynaecological cancer; Malignant-mesothelioma; Non-small cell lung cancer; Pancreatic cancer; Sickle cell anaemia

Most Recent Events

  • 28 Jun 2023 H. Lee Moffitt Cancer Center and Research Institute in collaboration with Merck completes a phase I trial in Gliosarcoma and Glioblastoma (Newly diagnosed, Combination therapy) in USA (PO) (NCT03426891)
  • 15 Jun 2023 Merck Sharp & Dohme in collaboration with University of California terminates a phase II trial in Breast cancer (Combination therapy, Late-stage disease) in USA (PO) due to low accrual (NCT04190056)
  • 02 Jun 2023 Updated adverse events and efficacy data from a phase I/II trial in Non-small cell lung cancer presented at the 59th Annual Meeting of the American Society of Clinical Oncology (ASCO-2023)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top